158 related articles for article (PubMed ID: 15920746)
21. Elevated levels of circulating endothelial progenitor cells in head and neck cancer patients.
Brunner M; Thurnher D; Heiduschka G; Grasl MCh; Brostjan C; Erovic BM
J Surg Oncol; 2008 Dec; 98(7):545-50. PubMed ID: 18792958
[TBL] [Abstract][Full Text] [Related]
22. Cytokines and tumor markers in potentially malignant disorders and oral squamous cell carcinoma: a pilot study.
Czerninski R; Basile JR; Kartin-Gabay T; Laviv A; Barak V
Oral Dis; 2014 Jul; 20(5):477-81. PubMed ID: 23859102
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
24. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.
Teknos TN; Cox C; Yoo S; Chepeha DB; Wolf GT; Bradford CR; Carey TE; Fisher SG
Head Neck; 2002 Nov; 24(11):1004-11. PubMed ID: 12410536
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Kane MA; List MA; Brockstein BE; Mehrotra B; Huo D; Mauer AM; Pierce C; Dekker A; Vokes EE
Clin Cancer Res; 2005 Dec; 11(23):8418-24. PubMed ID: 16322304
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and predictive value of serum vascular endothelial growth factor (VEGF) in squamous cell carcinoma of the head and neck.
Khademi B; Soleimanpour M; Ghaderi A; Mohammadianpanah M
Oral Maxillofac Surg; 2014 Jun; 18(2):187-96. PubMed ID: 23456015
[TBL] [Abstract][Full Text] [Related]
27. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
Mitsuhashi A; Suzuka K; Yamazawa K; Matsui H; Seki K; Sekiya S
Cancer; 2005 Feb; 103(4):724-30. PubMed ID: 15637689
[TBL] [Abstract][Full Text] [Related]
28. The impact of compliance in posttreatment surveillance in head and neck squamous cell carcinoma.
Deutschmann MW; Sykes KJ; Harbison J; Cabrera-Muffly C; Shnayder Y
JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):519-25. PubMed ID: 25950859
[TBL] [Abstract][Full Text] [Related]
29. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma.
Gourin CG; Moretz WH; Weinberger PM; Xia ZS; Liu Z; Terris DJ; Adam BL
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1125-30. PubMed ID: 18025317
[TBL] [Abstract][Full Text] [Related]
30. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling.
Linkov F; Lisovich A; Yurkovetsky Z; Marrangoni A; Velikokhatnaya L; Nolen B; Winans M; Bigbee W; Siegfried J; Lokshin A; Ferris RL
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):102-7. PubMed ID: 17220337
[TBL] [Abstract][Full Text] [Related]
31. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
32. Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma.
Alhamarneh O; Agada F; Madden L; Stafford N; Greenman J
Head Neck; 2011 Mar; 33(3):415-23. PubMed ID: 20645289
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood T-lymphocyte and monocyte function and survival in patients with head and neck carcinoma.
Heimdal JH; Aarstad HJ; Olofsson J
Laryngoscope; 2000 Mar; 110(3 Pt 1):402-7. PubMed ID: 10718427
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
35. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
36. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
37. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma.
Lim WS; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
Laryngoscope; 2017 Dec; 127(12):E437-E442. PubMed ID: 28561532
[TBL] [Abstract][Full Text] [Related]
39. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
40. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer.
Jebreel A; Mistry D; Loke D; Dunn G; Hough V; Oliver K; Stafford N; Greenman J
J Laryngol Otol; 2007 Mar; 121(3):246-52. PubMed ID: 17040593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
